Seres Therapeutics, Inc.
MCRB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,583 | $3,584 | $12,105 | $764 |
| - Cash | $31 | $128 | $163 | $180 |
| + Debt | $92 | $214 | $163 | $49 |
| Enterprise Value | $2,644 | $3,670 | $12,104 | $633 |
| Revenue | $0 | $0 | $0 | $145 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$4 | $0 | $0 | $145 |
| % Margin | – | – | – | 100% |
| EBITDA | -$120 | -$181 | -$171 | -$57 |
| % Margin | – | – | – | -39.1% |
| Net Income | $0 | -$114 | -$250 | -$66 |
| % Margin | – | – | – | -45.2% |
| EPS Diluted | -18.864 | -17.769 | -46.292 | -14.302 |
| % Growth | -6.2% | 61.6% | -223.7% | – |
| Operating Cash Flow | -$149 | -$117 | -$229 | $7 |
| Capital Expenditures | -$0 | -$8 | -$10 | -$10 |
| Free Cash Flow | -$149 | -$125 | -$239 | -$3 |